Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

Kaivan Khavandi, SVP at GSK, stated, "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for ...

Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

In Europe, asthma affects over 42 million people, with an estimated societal cost of 46 billion euros annually. CRSwNP, on the other hand, affects up to 4% of the general population, with 40% of ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Concerning CRSwNP, GSK intends to secure approval in adults. Similar regulatory filings for the drug have also been validated for review in China and Japan. If approved, depemokimab will be the ...